SCHEMBL14050602

SCHEMBL14050602

Cc1cc(Br)ccc1Nc1ncc(Br)c(Nc2cc(C3CC3)[nH]n2)n1

nearest known ligand 0.83

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ IGF1R P08069 20/20 0.83

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11339865 0.89 IGF1R (1.00) IGF1R
SCHEMBL11341560 0.88 IGF1R (1.00) IGF1R
SCHEMBL11342614 0.84 IGF1R (1.00) IGF1R
SCHEMBL12439789 0.82 IGF1R (0.56) IGF1R
SCHEMBL11347979 0.81 IGF1R (1.00) IGF1R
SCHEMBL11342672 0.80 IGF1R (1.00) IGF1R
SCHEMBL11341250 0.80 IGF1R (1.00) IGF1R
SCHEMBL11341596 0.80 IGF1R (1.00) IGF1R
SCHEMBL11346404 0.79 IGF1R (0.82) IGF1R
SCHEMBL11349121 0.79 IGF1R (1.00) IGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008127594-A2 COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER EXELIXIS, INC. (US) 2008-10-23 — — WO disclosed
WO-2008076415-A1 METHODS OF USING MEK INHIBITORS EXELIXIS, INC. (US) 2008-06-26 — — WO disclosed
WO-2008005538-A2 METHODS OF USING IGF1R AND ABL KINASE MODULATORS EXELIXIS, INC. (US) 2008-01-10 — — WO disclosed
Send feedback